Home  /  Resource Library  /  Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

ASH 2020: Results of a study examining Mosunetuzumab in combination with chemotherapy for first line treatment of unfit patients with DLBCL.